Waigaoqiao Launches Brain-Computer Interface Innovation Partnership with Fast-Track Regulatory Approval

WaigaoqiaoToday, the Brain-Computer Interface Innovation and Development Partnership Plan was announced, focusing on cross-border R&D, accelerated clinical approval, market expansion overseas, and diversified payment solutions, comprehensively speeding up the translation of brain-computer interface technology.

Located in the Waigaoqiao Bonded Area, the brain-computer interface company StairMed has independently developed the world's smallest brain-controlled implant. The device is only about the size of a coin, with a flexible electrode at the front that is less than one-hundredth the diameter of a hair, minimizing invasive damage during the implantation process.

"Implantable Wireless Brain-Computer Interface System" Recently Entered the National Medical Products Administration (NMPA)Innovative HealthcareSpecial Review Procedure for Devices, commonly known as the "Green Channel" in the industry. This is the first invasive brain-computer interface product in China to enter this procedure, and is considered an important milestone for industrialization.

Looking ahead, the company's director revealed that they are planning to initiate large-scale clinical trials next year, with a scale of approximately 30 to 40 cases. This is a critical period as they are actively discussing and designing implementation plans that meet the final registration requirements.

Previously, this company has collaborated with multiple medical institutions to conduct several prospective clinical trials, which have preliminarily verified the system's potential in motion control and assisting patients in regaining partial self-care abilities.

Brain-computer interface technology is on the verge of an explosion, transitioning from research to clinical application. Waigaoqiao, leveraging its "bonded R&D" policy function and its hub advantage connecting the Chinese and international markets, provides significant support for cutting-edge technologies like brain-computer interfaces. Particularly noteworthy is the upcoming partial opening of the Oriental Hub International Business Cooperation Zone by the end of the year, which will further unleash institutional opening-up dividends such as cross-border data flow, facilitation of personnel exchanges, and international medical services. These represent the "optimal coupling" of frontier technologies with regional core advantages.

Zhu Yaopeng, General Manager of Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd., stated that enterprises participating in global multicenter clinical trials will inevitably involve the free flow of data. The Oriental Hub International Business Cooperation Zone will undertake this functional positioning. Currently, they are formulating relevant industrial policies, including those for the biomedical sector.

The "Brain-Computer Interface Innovation and Development Partnership Program," jointly initiated by Waigaoqiao, enterprises, medical institutions, and government departments this time, will provide participating companies with full-chain support, covering key areas such as cross-border R&D pilots, accelerated clinical approvals, and market entry.

Check out the journalists: Chen Huiying, Gu Kejun

Editor: Zhang Yunpeng

Editor: Zhou Ti